Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Rediti M, Fernandez-Martinez A, Venet D, Rothé F, Hoadley KA, Parker JS, Singh B, Campbell JD, Ballman KV, Hillman DW, Winer EP, El-Abed S, Piccart M, Di Cosimo S, Symmans WF, Krop IE, Salgado R, Loi S, Pusztai L, Perou CM, Carey LA, Sotiriou C.
Rediti M, et al. Among authors: hoadley ka.
Nat Commun. 2023 Nov 3;14(1):7053. doi: 10.1038/s41467-023-42635-2.
Nat Commun. 2023.
PMID: 37923752
Free PMC article.
Clinical Trial.